GMOFORUM.AGROBIOLOGY.EU :  Phorum 5 The fastest message board... ever.
Goto Thread: PreviousNext
Goto: Forum ListMessage ListNew TopicSearchLog In
MIT-Engineered Peptide Targets COVID-19
Posted by: Prof. Dr. M. Raupp (IP Logged)
Date: July 01, 2020 08:52AM

Using computational models of protein interactions, researchers at the Massachusetts Institute of Technology Media Lab and Center for Bits and Atoms have designed a peptide that binds to coronavirus proteins and shuttles them into a cellular pathway that breaks them down. The researchers say this peptide has potential as a treatment that would prevent the SARS-CoV-2 virus from reproducing itself within infected cells.

Scientists from all over the world are pursuing many different strategies to develop new therapeutics against SARS-CoV-2, the coronavirus that causes COVID-19. One area of interest is developing antibodies that bind to and inactivate viral proteins such as the spike protein, which coronaviruses use to enter human cells. A related approach uses small protein fragments called peptides instead of antibodies.
The MIT team set out to engineer peptides that could strongly bind to the spike protein inside cells, and to use these peptides to trigger the cells to break down the viral proteins. They used a computational model of protein interactions that they had previously trained to optimize binding strength between two proteins. They then used their model to break ACE2 into many small fragments. The process generated about 25 candidate peptides, from which they found the best candidate, a 23-amino-acid peptide which broke down about 20 percent of the RBD proteins in the cells. To further improve the peptide's performance, the researchers used their model to simulate how its receptor-binding domain would be affected if they substituted different amino acids at each of its 23 positions. That optimization process yielded a mutant peptide that improved the degradation rate to over 50 percent.

Sorry, only registered users may post in this forum.
This forum powered by Phorum.